Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive

According to Reuters, operations at the new facility are expected to begin by the end of 2027.
Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)
Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Updated Jul 02, 2025 | 8:31 PM GMT-04
Share this article

French pharmaceutical major Sanofi SA (SNY) on Tuesday reportedly launched a vaccine manufacturing facility in Vietnam with Vietnam Vaccine JSC (VNVC). Following the news, Nasdaq-listed shares of Sanofi traded 2% higher in Tuesday’s premarket.

The new facility is designed to produce vaccines for use in Vietnam as well as for export, according to a Reuters report. It added that French President Emmanuel Macron, who is currently visiting Vietnam, witnessed the launch.

The plant spans 2.6 hectares and is situated in Long An. It has received an initial investment of two trillion dong ($77.15 million), the report said, citing a statement from VNVC.

The new facility is slated to produce 100 million vaccine doses annually, although it is unclear which vaccines will be produced.

Operations are expected to begin by 2027-end, the report added.

Sanofi, renowned for its vaccines, reported an 11.4% surge in vaccine sales in the first quarter to €1.3 billion ($1.48 billion). The company’s total sales in the quarter came in at €9.9 billion, marking an increase of 9.7% at constant exchange rate.

Sanofi makes vaccines against RSV lung infection, Polio, Influenza, whooping cough, and Meningitis, among others. The company is also developing and studying a vaccine against Chlamydia.

The company stated that over 500 million people are vaccinated annually with its vaccines worldwide, and it supplies 2.5 million vaccine doses every day.

On Stocktwits, retail sentiment around SNY stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.

SNY's Sentiment Meter and Message Volume as of 7:20 a.m. ET on May 27, 2025 | Source: Stocktwits
SNY's Sentiment Meter and Message Volume as of 7:20 a.m. ET on May 27, 2025 | Source: Stocktwits


According to Koyfin data, 16 of 21 analysts covering Sanofi rate it ‘Buy’ or higher, while five rate it a ‘Hold’.

SNY stock is up by about 8% this year and by over 8% over the past 12 months.

Read Next: Info Edge Tests Key Support: SEBI RA Financial Sarthis Says Breakout Above ₹1,510 Could Signal Upside

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Subscribe to Trends with No Friends
All Newsletters
High Relative Strength, Low Social Following

Exchange Rate: 1 Vietnamese Dong = 0.000039 USD
                            1 Euro = 1.14 USD

Read about our editorial guidelines and ethics policy

Advertisement. Remove ads.